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The convergent human immunodeﬁciency virus (HIV) and tuberculosis (TB) pandemics continue to collectively exact signiﬁcant
morbidity and mortality worldwide. Highly active antiretroviral therapy (HAART) has been a critical component in combating
the scourge of these two conditions as both a preemptive and therapeutic modality. However, concomitant administration
of antiretroviral and antituberculous therapies poses signiﬁcant challenges, including cumulative drug toxicities, drug-drug
interactions, high pill burden, and the immune reconstitution inﬂammatory syndrome (IRIS),thus complicating the management
of coinfected individuals. This paper will review data from recent studies regarding the optimal timing of HAART initiation
relative to TB treatment, with the ultimate goal of improving coinfection-related morbidity and mortality while mitigating toxicity
resulting from concurrent treatment of both infections.
1. Convergence of HIV/TB Pandemics
There are approximately 33 million HIV-infected persons
worldwide, of whom approximately 2 million are children
[1]. An estimated 2 million deaths have been attributed
annuallytoHIV/AIDS,withapproximately250,000pediatric
deaths. One third of the world’s population is infected with
Mycobacterium tuberculosis. In 2007, there were approxi-
mately9.3millionincidentcasesofTB[2],withanestimated
1 million of these occurring in children [3].
TheHIVpandemic hasfueledariseinbothTBincidence
and mortality, with an approximately 40% increase in
incident TB cases compared to 20 years ago [4]. In the USA,
one quarter of all TB cases occur in HIV-infected persons
[5] and worldwide an estimated 1.37 million (14.8%) TB
casesoccurinHIV-positivepersons,resultingin456,000TB-
related deaths in this population [2]. HIV/TB coinfection is
particularly prevalent in populations with limited resources.
Thus, the prevalence of HIV infection among patients with
TB ranges from 50% to 80% in sub-Saharan Africa, as
compared to 2–15% in other parts of the world.
HIV/TB coinfected persons have been shown to have
a higher mortality rate than those without either infection
alone, regardless of CD4 count [6]. TB accounts for 26%
of AIDS-related deaths worldwide and 29% of TB-related
mortality has been attributed to HIV infection [2].
An estimated 500,000 cases of multidrug-resistant
(MDR) TB (deﬁned as resistance to the ﬁrst line agents
rifampin and isoniazid) occur annually [7], with a sim-
ilar prevalence among HIV-infected persons as for HIV-
uninfected persons, as MDR-TB strains do not appear
to be more transmissible or pathogenic in the setting of
HIV/AIDS. However, relative to the general population, fac-
tors such as congregation, delayed diagnosis, and inadequate
initial treatment, contribute to periodic outbreaks of MDR-
TB in HIV-infected populations [8]. Moreover, outbreaks
of extremely drug-resistant (XDR) TB (deﬁned as MDR-TB
plus resistance to any ﬂuoroquinolone and at least one of the
three injectable second-line drugs capreomycin, kanamycin,
andamikacin)havebeenreportedwithincreasingfrequency,
with particularly deadly consequences for HIV-coinfected
individuals [9].2 Clinical and Developmental Immunology
2. Pathogenesis of HIV/TB Coinfection
T h ef a t eo fM. tuberculosis infection in the human host is
dependent in large part on host innate and adaptive immune
responses.Initialrecognitionofthetuberclebacillusdepends
upon innate immune receptor recognition of conserved
pathogen-associated molecular patterns (PAMPs) of M.
tuberculosis [10–12]. In the appropriate host cellular envi-
ronment, the adaptive immune system is primed to contain,
but usually not eradicate, the infection within necrotic
granulomas, leading to latent TB infection. In particular,
CD4 T cells are critical in the control of M. tuberculosis
infection, as quantitative and qualitative deﬁciencies of these
eﬀector cells in HIV-infected individuals increase the rates of
bothprimaryandreactivationdisease.Whilethelifetimerisk
of developing active TB is approximately 10% for immune-
competent persons following initial infection, for persons
with HIV coinfection the annual risk can exceed 10% [13],
and the risk of TB reactivation rises as the CD4 cell count
declines [14–16].
3. Prevention of Active TB in
HIV-PositivePatients
Treatment of latent TB infection with isoniazid is highly
eﬀective in preventing the progression to active disease
amongHIV-infectedpersons[17,18].Arecentmeta-analysis
of randomized controlled trials revealed a reduction in the
incidence of active TB of over 30% in persons receiving
chemoprophylactic treatment compared to those receiving
placebo [19].
HAART also has been found to play an important
role in preventing the development of active TB in HIV-
positive patients, reducing the incidence of TB by up to
90% in patients receiving such therapy relative to those not
receivingantiretroviraldrugs[20–22].However,despiteviral
suppression with HAART, the risk of TB remains higher
in HIV-infected persons than in HIV-uninfected persons,
suggesting incomplete immune restoration in the former
group [23].
4. PotentialChallenges in the Treatment of
HIV-AssociatedTB
The concomitant treatment of HIV and active TB poses
signiﬁcant challenges, particularly relating to the duration
and frequency of dosing of anti-TB drugs and the optimal
timing of HAART initiation relative to TB treatment, which
has important consequences vis-` a-vis overlapping drug
toxicities and drug-drug interactions between anti-TB drugs
andantiretroviraldrugsaswellastheimmunereconstitution
inﬂammatory syndrome (IRIS).
Although current guidelines recommend a 6-month
rifamycin-based regimen for treatment of drug-susceptible
pulmonary TB regardless of HIV status [24], the results
of two randomized trials suggest that relapse rates after
such therapy may be higher among HIV-infected persons
than among HIV-uninfected persons [25, 26]. A recent
meta-analysis of randomized, controlled trials and cohort
studies found that at least 8 months duration of rifamycin-
based therapy, daily drug dosing during the initial phase
of treatment, and concurrent antiretroviral therapy are
associated with improved outcomes in HIV-associated TB
[27]. Although intermittent dosing under direct observation
is a mainstay of TB treatment regimens in the USA and
elsewhere,highlyintermittent(onceortwiceweekly)therapy
has been associated with increased relapse rates in HIV-
infected persons, often with acquired rifamycin resistance
[28, 29].
Concurrent treatment of TB and HIV is associated with
a higher risk of adverse reactions compared to treatment
of either infection alone. In particular, the ﬁrst-line anti-
tuberculous drugs isoniazid, rifampin, and pyrazinamide
may each cause hepatotoxicity, which may be compounded
by concurrent use of protease inhibitors and nonnucleo-
side reverse transcriptase inhibitors [30, 31]. Since HIV-
infected persons are at increased risk for isoniazid-induced
peripheral neuropathy, these patients should take vitamin
B6 and avoid antiretroviral drugs with potential peripheral
neurotoxicity (e.g., stavudine and didanosine). Additionally,
gastrointestinal distress and high pill burden can contribute
to reduced tolerability and adherence to a combined TB/HIV
therapeutic regimen.
Pharmacokinetic interactions between HIV and TB
regimens can have a signiﬁcant impact on the therapeutic
eﬃcacy of each regimen. Potent induction of the cytochrome
p450 system by rifampin can lead to subtherapeutic levels of
the protease inhibitors accompanied by virological failure.
Rifabutin, another rifamycin with less potent induction
of the p450 system, may be used together with protease
inhibitors, but its dose must be decreased to avoid rifabutin-
related toxicity. However, rifabutin is not readily available in
many resource-limited settings [32]. Rifampin also reduces
levels of the nonnucleoside reverse transcriptase inhibitors
efavirenz and nevirapine. Although these interactions do not
appear to have a deleterious eﬀect on virological outcomes
with efavirenz-based therapy, increased rates of virological
failure have been reported with concomitant nevirapine use
[33, 34].
Initiation of antiretroviral therapy in HIV/TB-coinfected
individuals can also result in an initial paradoxical clinical
deterioration known as IRIS. IRIS has been reported in
up to 30% of HIV-infected persons subsequent to HAART
initiation [35–37]. Individuals with low initial CD4 counts,
who experience a rapid rise in their CD4 cell count or
rapid decline in their HIV viral load soon after initiating
HAART, are at increased risk for developing IRIS [38–41].
TB-related IRIS may manifest as high fever, worsening pul-
monary inﬁltrates and respiratory compromise, increasing
lymphadenopathy, and neurological deterioration with the
potential for severe morbidity and mortality [38–48].
Despite the signiﬁcant challenges posed by concomitant
treatment of HIV and TB infections, delaying HAART until
after the completion of TB treatment in coinfected persons
may carry its own attendant risks. As early antiretroviral
therapy in HIV-infected persons has been shown to reduce
the risk of AIDS progression and death [49], concerns haveClinical and Developmental Immunology 3
been raised that even brief delays in HAART initiation can
lead to substantial increases in mortality [50]. Therefore,
therehasbeensigniﬁcantinterestrecentlyindeterminingthe
optimal timing of HAART initiation relative to TB treatment
in the setting of HIV-associated TB.
5. Optimal Timingof AntiretroviralTherapy in
HIV/TB-CoInfected Persons
Leonard et al. studied HIV/TB coinfected individuals, who
were followed between 1991 and 1997 at a single center in
Atlanta, Georgia [51]. Increased one year survival rates were
observed in the 1994 and 1997 patient cohorts compared to
the 1991 cohort, suggesting a correlation between increased
survival and concurrent antiretroviral and anti-TB therapy,
although a direct role for HAART in improved clinical
outcomes could not be inferred from this study (see Table 1).
Three studies based in Thailand attempted to elucidate
the risks and beneﬁts of concomitant treatment of HIV
and TB in coinfected individuals. A retrospective study by
Sungkanuparph et al. at a single site in Thailand evaluated
29 adult patients with HIV/TB coinfection, all with CD4
countslessthan200[52].Antiretroviraltherapywasinitiated
between 4 and 12 weeks after initiation of antituberculous
therapy, based on clinical stability on the TB regimen. A
single death in this cohort was attributed to CMV infection,
and one case of IRIS was observed. Additional reported
adverse events included rash with nevirapine, dizziness with
efavirenz, and anemia with d4T. Although this study was
limited by the relatively small sample size and lack of a
control group, 26 of the 29 patients were able to complete a
full course of TB treatment while taking antiretroviral drugs,
suggesting the potential tolerability of dual therapy.
Manosuthi et al. subsequently performed a larger retro-
spective cohort study with approximately 1000 adult HIV-
infected persons with active TB diagnosed by clinical symp-
toms and positive sputum acid-fast smear [53]. A uniform
anti-TB regimen was administered with the standard initial
2-month regimen comprising isoniazid, rifampin, pyrazi-
namide, and ethambutol, followed by 4 months of isoniazid
andrifampin.Therewassomevariabilityintheantiretroviral
regimen employed with 80% of individuals receiving a
nevirapine-based regimen, 16% an efavirenz-based regimen,
and the remainder receiving a protease inhibitor-based
regimen. Concurrent TB treatment and HAART appeared to
confer a signiﬁcant survival beneﬁt, with a mortality rate of
7.7% in the group receiving both treatments, compared to
67.7% in the group receiving TB treatment alone. Although
this study was limited by the greater underlying morbidity in
thegroupnotreceivingHAART,withmoreadvancedTBand
higher rates of drug resistance noted in this group, subgroup
analysis demonstrated signiﬁcantly greater survival among
patients receiving HAART within 6 months of TB diagnosis
as compared to those receiving HAART beyond 6 months
of TB diagnosis. However, patients in whom HAART was
started within 2 months of TB treatment initiation did not
appeartohaveimprovedsurvivalrelativetothosewhobegan
receiving HAART 4 months after initiating TB treatment.
A third Thai-based study by Sanguanwongse et al. also
attempted to evaluate the role of HAART on survival
of HIV/TB-coinfected individuals [54]. This observational
cohort study evaluated 626 HIV/TB-coinfected patients
receiving HAART together with TB treatment and 643
HIV/TB-coinfected patients receiving TB treatment alone.
A signiﬁcant decline in mortality was observed in the
group receiving concurrent HAART (11%) compared to the
group not receiving HAART (46%). Although this study
was nonrandomized and precise information on the HAART
regimen employed for each patient was lacking, it provided
further support for the potential beneﬁt of concomitant
HAART and TB treatment.
Five recent studies have attempted to address the appro-
priate timing of initiation of HAART in HIV/TB-coinfected
patients. A small retrospective study in Tehran involving
69 individuals with HIV/TB coinfection was divided into 2
groups [55]. One group, treated from 2002 to 2005, received
HAART after 8 weeks of TB treatment if the CD4 count was
less than 200. The second group, treated from 2005 to 2006,
received HAART after 2 weeks of TB treatment if the CD4
count was less than 100 and after 8 weeks if the CD4 count
was between 101 and 200. A lower mortality rate and higher
rate of TB cure was observed in the latter group suggesting
that early initiation of HAART may be beneﬁcial at lower
CD4 counts in HIV-associated TB. No diﬀerence in adverse
events including IRIS and new opportunistic infections was
reported between these 2 groups [55].
A partially retrospective, multicenter study in Madrid,
Spain compared HAART initiation within 2 months of TB
diagnosis to HAART initiation 3 months subsequent to TB
diagnosis[56].Nodiﬀerenceinvirologicalorimmunological
outcomeswasobservedbetweenthese2groups,althoughthe
early HAART group had lower mean baseline viral loads.
However, early HAART initiation (within 2 months) was
associated with improved survival [56].
The aforementioned studies were primarily observa-
tional and retrospective in nature. The need for prospective
randomized controlled trials to address the clinically impor-
tant question of the optimal timing of HAART initiation
relativetoantituberculoustherapyledtothedesignofseveral
such trials in recent years [60]. The Starting Antiretroviral
Therapy at Three Points in Tuberculosis (SAPIT) trial, an
open label, randomized controlled trial conducted in a
large clinic in Durban, South Africa [58], enrolled HIV-
positive adult patients with a CD4 count <500 and AFB
smear-positive TB. The TB regimen consisted of a 2-month
standard initial phase with rifampin, isoniazid, ethambutol,
and pyrazinamide for TB treatment-na¨ ıve individuals, with
the addition of streptomycin for treatment-experienced
individuals, followed by rifampin and isoniazid during the
continuation phase. All patients received the same HAART
regimen (didanosine, lamivudine, and efavirenz) and coun-
seling regarding medical adherence. There were 3 main arms
of this study: a sequential therapy arm in which patients
received HAART subsequent to completion of TB treatment,
an early integrated therapy arm in which patients received
HAART within 4 weeks after the start of TB treatment,
and a late integrated therapy arm in which HAART was4 Clinical and Developmental Immunology
Table 1: Studies on initiation of highly active antiretroviral therapy (HAART) in HIV/TB-coinfected individuals.
Study (author, year) Study characteristics Timing of HAART
relative to TB treatment Outcomes Adverse events
Leonard et al.
2002 [51]
-R e t r o s p e c t i v ec o h o r t
- 644 adults and children
(60% pulmonary TB, 25%
pulmonary and
extrapulmonary TB, 15%
extrapulmonary TB)
- Single center — Atlanta, GA
- Comparison of 3 HIV/TB
coinfected cohorts: 1991,
1994, 1997
HAART at time of
diagnosis versus HAART
post-TB diagnosis —
not deﬁned
Decreased 1 year
mortality in 1994 and
1997 cohort compared
to 1991 cohort
N/A
Sungkanuparph
et al. 2006 [52]
- Retrospective, observational
- 29 adult patients (69%
pulmonary TB, 31%
extrapulmonary TB)
- Jan 2002–Dec 2002
- Single center—Thailand
Median 8 weeks (range
4–12 weeks)
Virological suppression
-65% at 24 weeks
-76% at 48 weeks
TB outcomes
-26/29 completed
therapy
-No relapse
-No new OI
IRIS—1/29
Death—1/29 (CMV
encephalitis)
Rash—2/29 (NVP)
EFV switched to NVP 1/29
(dizziness)
AZT switched to D4T 3/29
(anemia)
Manosuthi et al.
2006 [53]
-R e t r o s p e c t i v ec o h o r t
- 1003 adult patients
- Jan 2000–Dec 2004
- Single center — Thailand
- Comparison of HAART+ to
HAART− group
2mthversus4mth
versus
6mthversus9mth
versus
12mth (subgroup
analysis)
Increased survival for
pts. receiving HAART as
compared to no HAART
Increased mortality with
HAART initiation at
>6mths. (11.3%)
compared to <6mths
(4.1%) (P = .018)
N/A
Sanguanwongse
et al. 2008 [54]
-O b s e r v a t i o n a lc o h o r t
- 1269 patients (adult and
pediatric) (54% pulmonary
TB, 35% extrapulmonary TB,
12% both)
- Oct 2004–March 2006
- Multicenter — Thailand
National Surveillance Network
Not deﬁned
Decreased mortality in
group receiving HAART
(11%) compared to that
not receiving HAART
(46%) (relative risk 0.24,
95% conﬁdence interval:
0.19 to 0.30)
N/A
Tabarsi et al.
2009 [55]
-R e t r o s p e c t i v ec o h o r t
- 69 patients
- 2002–2006
G r o u pI :H A A R Ta f t e r
8wks if CD4 < 100
Group II: HAART at
2wks if CD4 < 100
Group I & II: HAART
after 8wk if CD4
101–200
Increased mortality
when HAART deferred
after 8 weeks if CD4
<100 Group I versus
Group II mortality =
27.7% versus 4.5%
( P = .03)
No diﬀerence between
groups I and II regarding
Grade 3 or 4 events, IRIS,
or new OI
Velasco et al.
2009 [56]
-M i x e dr e t r o s p e c t i v e /
prospective study
- 313 patients
- 1996–2004
- Simultaneous: HAART
within 2mths of TB
diagnosis
- Nonsimultaneous:
HAART after 3mths of
TB diagnosis
- Decreased mortality in
simultaneous group
(9.3%) versus
nonsimultaneous group
(19.7%) (P = .011)
-N od i ﬀerence in viro-
logical/immunological
outcomes
N/A
Torok et al.
2009 [57]
- Randomized, double blind,
placebo-controlled trial
- 253 patients
-V i e t n a m
- Clinical diagnosis of TB
meningitis
HAART started within 7
days (immediate arm) or
at 2mths (deferred arm)
after initiation of TB
treatment
Mortality:
-Immediate arm: 76
deaths/127pts
-Deferred arm: 70
deaths/126pts
(HR = 1.16, P = .31)
Incidence of grade 3 or 4
adverse events ﬁrst 2mths:
-Immediate: 86%
-Deferred: 75% (P = .04)Clinical and Developmental Immunology 5
Table 1: Continued.
Study (author, year) Study characteristics Timing of HAART
relative to TB treatment Outcomes Adverse events
Abdool Karim
et al. 2010 [58]
- Open-label, randomized,
controlled trial
- 642 patients
- Durban, South Africa
- Only patients with positive
sputum smear for acid-fast
bacilli and CD4 count <
500/mm3 included
HAART started either
during TB treatment (in
two integrated-therapy
groups) or after
completion of TB
treatment (in one
sequential-therapy
group)
Mortality rate per
100py:
- I n t e g r a t e da r m :5 . 4
-Sequential arm: 12.1
(P = .003) Virological
suppression 6mths after
HAART initiation:
-Integrated arm: 91.1%
-Sequential arm: 86.7%
(P = .4)
Incidence of IRIS:
-Integrated arm: 12.4%
-Sequential arm:
3.8% (P ≤ .001)
Grade 3 or 4 adverse events:
Integrated arm: 30/100py
Sequential arm: 32/100py
(P = .69)
Blanc et al.
2010 [59]
- Open label randomized,
controlled trial
- 661 patients
- Cambodia
- Only patients with positive
smear for acid-fast bacilli and
CD4 count < 200/mm3
included
HAART started at 2
weeks (early arm) or 8
weeks (late arm) after
initiation of TB
treatment
Mortality rate per
100py:
-Early arm: 8.28
-Late arm: 13.77
(P = .002) Virological
suppression 50wks after
HAART initiation:
-Early arm: 95.6%
-Late arm: 95.6%
(P = .82)
Incidence of IRIS per 100
pm:
-Early arm: 4.03
-Late arm: 1.44 (P<. 0001)
OI:OpportunisticinfectionsIRIS:ImmunereconstitutioninﬂammatorysyndromeEFV:EfavirenzNVP:Nevirapinepts:PatientsHR:Hazardratiopy:Person-
years pm: Person-months N/A: Not available.
administered within 4 weeks after completion of the initial
phase of treatment. Patients were randomly assigned to one
of these 3 groups and the primary outcome was all-cause
mortality. The sequential therapy arm was stopped early
by the data and safety monitoring committee upon interim
analysis of the data. A signiﬁcant 56% decline in mortality
was observed in the combined integrated arms compared
to the sequential arm, with a mortality rate of 5.4 per 100
person-years in the former group as compared to 12.1/100
person-years in the latter group. Similar rates of virological
suppression were observed in each of the groups after similar
duration of HAART, and no diﬀerence was observed in grade
3 and grade 4 events between the groups.
TheinitialﬁndingsoftheSAPITtrialprovidecompelling
evidence for the superiority of integrated versus sequential
antituberculous and antiretroviral therapy for coinfected
individuals. Further elucidation of the precise timing of
HAARTinitiationrelativetoTBtreatmenthasbeenprovided
recently by the Cambodian Early versus Late Introduction
of Antiretrovirals (CAMELIA) trial [59]. This study was
an open label, prospective, randomized controlled trial
enrolling HIV-positive adult patients with a CD4 count
<200/mm3 and AFB smear-positive TB at 5 sites in rural
and urban Cambodia. Patients were treated with a 2-month
intensivephaseTBregimenconsistingofrifampin,isoniazid,
pyrazinamide, and ethambutol, followed by a 4 month
continuation phase regimen of rifampin and isoniazid.
Participants were randomized to 2 arms, an early arm
in which HAART was introduced 2 weeks subsequent to
the initiation of antituberculous therapy and a late arm
in which HAART was introduced 8 weeks subsequent to
the initiation of antituberculous therapy. Patients in each
arm received a HAART regimen consisting primarily of
lamivudine,stavudine,andefavirenz.Thepreliminaryreport
from this study noted a signiﬁcant 34% decline in mortality
in the early HAART arm compared to the late HAART arm,
with a mortality rate of 8.28 per 100 person-years in the early
arm as compared to 13.77 per 100 person-years in the late
arm. Similar rates of virological suppression were observed
in both groups.
The AIDS Clinical Trials Group recently completed
a study entitled “A Strategy Study of Immediate Ver-
sus Deferred Initiation of Antiretroviral Therapy for HIV
Infected Persons Treated for Tuberculosis With CD4 Less
Than 200Cells/mm3”[ 61]. This study was an open-label,
randomized controlled trial conducted between August 2006
and July 2010, which enrolled persons aged >13 years old
with CD4 count less than 200cells/mm3 and conﬁrmed or
probable TB. Participants were assigned to early initiation
of HAART within 2 weeks after initiating TB treatment,
or deferral of HAART until 8 to 12 weeks after initiation
of TB treatment. The majority of participants received
efavirenz, tenofovir, and emtricitabine and the primary
outcome measure was the proportion of participants who
have survived without AIDS progression. The analysis of this
study is pending.
6. Conclusions andFutureDirections
The ﬁndings of multiple retrospective studies and of the
prospective randomized SAPIT and trial provide compelling
evidence that initiation of HAART should not be delayed
pending completion of TB treatment for HIV/TB-coinfected
individuals. The most recent WHO guidelines for antiretro-
viral therapy in adolescents and adults recommend the6 Clinical and Developmental Immunology
initiation of HAART between 2 and 8 weeks subsequent to
the initiation of TB therapy for severely immunosuppressed
coinfected individuals, as deﬁned by a CD4 count <200mm3
[62]. The preliminary reported ﬁndings from the CAMELIA
trial provide evidence that coinfected individuals with CD4
counts <200mm3 would beneﬁt from HAART initiation
early during this intensive phase of TB treatment, that is at
2 weeks as opposed to deferral of HAART to 8 weeks after-
initiation of TB therapy [59]. Further multicountry data on
the timing of HAART for coinfected individuals with CD4
counts <200mm3 is likely to be provided by the recently
concluded ACTG A5221 study [61].
An increased risk of IRIS was observed in the integrated
arm of the SAPIT trial (12% in the integrated arm versus
3.8% in sequential arm) as well as in the early arm of the
CAMELIA trial (4.03 per 100 person months in the early
arm versus 1.44 per 100 person months in the late arm),
consistent with the ﬁndings of previous studies regarding the
development of IRIS relative to HAART initiation [63–66].
However, the lack of mortality or changes in antiretroviral
regimen attributable to IRIS in the SAPIT trial, coupled
with the ﬁndings of a prior modeling study demonstrating
the beneﬁt of early HAART initiation in the setting of
low mortality rates from TB-IRIS [67], provides further
support for early HAART initiation in persons with HIV-
associated TB. Although guidelines have been developed
speciﬁcally for resource-limited settings [68], the ability to
detectandappropriatelytreatIRISinatimelyfashionoutside
a controlled study environment requires further study.
The risk of IRIS may vary depending on the type
of opportunistic pathogen in a site-speciﬁc manner. This
concept may be of particular clinical relevance for central
nervous system (CNS) infections. CNS-IRIS occurs after
HAART initiation in approximately 1% of cases [69].
Immune restoration in the setting of CNS opportunistic
infections can lead to increased intracranial pressure as a
result of the inﬂammatory response in a relatively closed
space, with potentially irreversible neurologic sequelae [70,
71]. High mortality rates have been reported in cases of
CNS IRIS, including up to 57% for such pathogens as
Cryptococcus neoformans [72, 73]. A recent study showed
increased mortality with early initiation of HAART in the
setting of concomitant HIV/cryptococcal meningitis [74].
Extrapulmonary TB, including CNS disease (manifesting
as tuberculous meningitis or CNS tuberculoma), may
demonstrate a diﬀerent clinical course relative to primary
pulmonary disease post-HAART initiation [43, 45, 74–77].
It should be noted that the great majority of patients
included in the SAPIT trial had exclusively pulmonary TB,
not allowing conclusions to be drawn regarding the optimal
timing of HAART initiation in the setting of CNS and other
f o r m so fe x t r a p u l m o n a r yT B .W h e r e a sag r e a t e rp r o p o r t i o n
of participants in the CAMELIA trial had extrapulmonary
TB, it is not certain whether subgroup analysis by location
of involvement could be performed. However, preliminary
reports of a single center randomized trial in Vietnam
examining HAART initiation in patients with HIV and
CNS-TB suggested no mortality diﬀerence in the group
treated immediately with HAART (within 7 days of TB
treatment) as compared to the group in whom HAART
was deferred (2 months post-randomization) [57]. However,
there were higher rates of grade 4 adverse events in the
immediate HAART arm, suggesting that deferral of HAART
initiation to the continuation phase of TB treatment may be
warranted in the setting of HIV and CNS-TB coinfection.
The optimal timing of HAART initiation for individuals
with extrapulmonary TB, as well as for those with other
opportunistic infections, requires further study.
As for adults, HIV is a major risk factor for the devel-
opment of pediatric TB [78]. Recommendations for deferral
of HAART until after completion of TB treatment for
children with mild or insigniﬁcant immunodeﬁciency had
initially been proposed. The most recent WHO guidelines
recommend initiation of HAART as soon as tuberculosis
therapy is tolerated, ideally as early as 2 weeks and no
later than 8 weeks subsequent to initiation of TB treatment,
regardlessofclinicalstageanddegreeofimmunosuppression
[79]. However, studies on the optimal timing of HAART
initiation among children with TB have been limited to
observationalreports,althougharecentsuchstudysuggested
a trend towards decreased mortality and higher rates of
virological suppression with earlier HAART initiation in
this age group [80]. Extrapolation of ﬁndings from adult
studies to the pediatric population may not be possible
given potential diﬀerences in pharmacokinetics and phar-
macodynamics as well as challenges in deﬁnitive pediatric
TB diagnosis. Further data is required to evaluate current
recommendations for this speciﬁc population.
HIV patients with drug-resistant TB demonstrate
reduced survival compared to those with drug-susceptible
TB [9, 53, 81]. Many additional challenges exist in the
comanagement of MDR-TB and XDR-TB among HIV-
positive populations, including delays in the diagnosis of
drug resistance, and inadequate infection control modalities,
as well as the decreased eﬃcacy, prolonged duration, and
increased cost of therapeutic regimens compared to those
for drug-susceptible TB [82]. Moreover, second- and third-
line TB regimens demonstrate their own distinct cumulative
toxicities with concomitant HAART administration. For
instance, the nephrotoxicity associated with tenofovir may
be compounded by the antituberculous aminoglycosides
and the peripheral neurotoxicity induced by stavudine and
didanosine and psychiatric disturbances associated with
efavirenz may be exacerbated by the antituberculous agent
cycloserine. Additionally, the pill burden and gastrointestinal
distress associated with drug-susceptible TB regimens are
even greater with MDR-TB and XDR-TB regimens [82, 83].
The timing of HAART initiation in the setting of drug-
resistant TB thus requires careful consideration of both
the unique cumulative toxicities as well as the distinctive
pharmacokinetic interactions between antiretroviral drugs
and second- and third-line TB regimens [84]. Further
investigation is warranted to determine if the ﬁndings of
the SAPIT and CAMELIA studies are applicable to persons
coinfected with HIV and drug-resistant TB. Moreover, the
anticipated emergence of HIV resistance in resource-limited
settings will further complicate the management of HIV/TB
coinfected patients.Clinical and Developmental Immunology 7
Several studies have shown a beneﬁt to initiating HAART
at higher CD4 counts [85–87]. As a consequence, WHO
has recently increased the recommended CD4 threshold for
HAART initiation from 200 to 350/mm3 for stage 1 or 2
disease [62]. HAART initiation at even higher CD4 counts
has been recommended by other groups [88]. Whereas
tuberculosis is a recommended indication for initiation
of HAART at any CD4 count, the WHO guidelines state
that “there are limited data on the initiation of ART in
patients with TB and CD4 counts of >350cells/mm3”[ 62].
The SAPIT trial suggested a trend towards a mortality
beneﬁt when HAART was initiated in persons with CD4
counts of 200–500/mm3 in the integrated groups com-
pared to the sequential group though the sample size in
this subgroup was small. Although the CAMELIA trial
addresses the management of HIV/TB coinfected persons
with CD4 counts <200/mm3, recommendations regarding
the optimal timing of HAART for coinfected individuals
with CD4 counts >200/mm3 may not be derived from
this trial or from the recently concluded ACTG A5221
study. Such a determination, with signiﬁcant implications
for the management of HIV/TB coinfection worldwide,
awaits future study, including the results of the comparative
analysis of the early and late integrated arms of the SAPIT
trial.
Only approximately 42% of those in need worldwide
currently receive HAART [89]. The appropriate treatment of
HIV/TB-coinfected individuals has the potential to signiﬁ-
cantly reduce morbidity and mortality globally, however the
ability to deliver such treatment remains a critical challenge.
The available data should provide an impetus for improving
access to both life-saving HIV and TB medications to all
those in need of such therapy.
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